From Wilsons report 2016 'Oncosil Medical has made its first submission to the FDA, seeking approval to trial its brachytherapy device for the treatment of pancreatic cancer. A well-designed, pivotal clinical trial is required to support a future application to market the product in the US. Later this quarter, the FDA’s response letter and further trial design detail should come to light, clarifying the pathway towards US licensure. Meanwhile, the European approval process has encountered a longer review period than expected, but we remain confident. We maintain a SPECULATIVE BUY rating. Target price upgraded to 50 cps (risked) with potential, milestone-dependent upside to $1/share over the next 12 months.'
Yes, how cute is that. Does anyone actually pay for Wilsons research apart from the companies whose shares are being spriuked?
OSL Price at posting:
1.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)